Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one.
Sanofi (NYSE: SNY) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: TBIO), a Lexington, MA-based developer of mRNA therapies. The companies are already partners. In 2018, they began a three-year alliance aiming to develop vaccines for up to five infectious diseases. The COVID 19 research tacks a sixth vaccine target onto that pact.
For Sanofi… Read more »
UNDERWRITERS AND PARTNERS
